AnaptysBio, Inc. (ANAB) Financial Ratios
13 years of historical data (2013–2025) · Healthcare · Biotechnology
EV/EBITDA
45.66
↑+191% vs avg
5yr avg: 15.68
30Y Low15.7·High15.7
P/FCF
128.60
↑+149% vs avg
5yr avg: 51.66
30Y Low51.7·High51.7
P/B Ratio
↑
49.26
↑+529% vs avg
5yr avg: 7.83
30Y Low0.7·High27.2
ROE
↓
-24.5%
↓+66% vs avg
5yr avg: -71.5%
30Y Low-183%·High8%
Debt/EBITDA
0.28
+0% vs avg
5yr avg: 0.28
30Y Low0.3·High1.0
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
ANAB Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
AnaptysBio, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis. On a free-cash-flow basis, the stock trades at 128.6x P/FCF, 149% above the 5-year average of 51.7x.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $2.5B | $1.0B | $251M | $384M | $582M | $636M | $391M | $293M | $1.0B | $1.3B | — |
| Enterprise Value | $2.3B | $789M | $497M | $366M | $530M | $161M | $141M | $125M | $944M | $1.3B | — |
| P/E Ratio → | -127.13 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 10.75 | 4.32 | 2.75 | 22.41 | 56.57 | 10.06 | 5.22 | 36.63 | 209.87 | 132.84 | — |
| P/B Ratio | 49.26 | 27.22 | 3.54 | 4.36 | 2.22 | 1.78 | 0.99 | 0.72 | 2.16 | 4.32 | — |
| P/FCF | 128.60 | 51.66 | — | — | — | — | — | — | — | — | — |
| P/OCF | 128.03 | 51.43 | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
ANAB EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
AnaptysBio, Inc.'s enterprise value stands at 45.7x EBITDA, 191% above its 5-year average of 15.7x. The Healthcare sector median is 14.3x, placing the stock at a 218% premium on an enterprise-value basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 3.36 | 5.44 | 21.35 | 51.52 | 2.55 | 1.88 | 15.62 | 188.80 | 126.16 | — |
| EV / EBITDA | 45.66 | 15.68 | — | — | — | — | — | — | — | — | — |
| EV / EBIT | 47.97 | 16.47 | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | 40.23 | — | — | — | — | — | — | — | — | — |
ANAB Profitability
Margins and return-on-capital ratios measuring operating efficiency
AnaptysBio, Inc. earns an operating margin of 20.4%. Operating margins have expanded from -958.3% to 20.4% over the past 3 years, signaling improving operational efficiency. A negative ROE of -24.5% indicates the company is currently destroying shareholder equity. ROIC of 55.1% represents excellent returns on invested capital.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 99.0% | 99.0% | -79.5% | -671.0% | -763.2% | -55.9% | -6.7% | -1141.7% | -1023.9% | -194.4% | 7.6% |
| Operating Margin | 20.4% | 20.4% | -125.9% | -958.3% | -1119.4% | -89.9% | -31.8% | -1342.9% | -1334.4% | -287.8% | -18.1% |
| Net Profit Margin | -5.6% | -5.6% | -159.1% | -953.7% | -1251.3% | -91.5% | -26.6% | -1216.7% | -1233.1% | -300.7% | -25.5% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -24.5% | -24.5% | -182.7% | -93.4% | -41.6% | -15.3% | -5.0% | -21.8% | -15.5% | -17.3% | -10.4% |
| ROA | -3.1% | -3.1% | -31.0% | -30.8% | -20.5% | -10.9% | -4.7% | -20.6% | -14.7% | -15.4% | -7.2% |
| ROIC | 55.1% | 55.1% | -44.5% | -88.0% | -188.0% | -301.4% | -9.3% | -26.1% | -16.1% | -17.8% | — |
| ROCE | 12.5% | 12.5% | -26.9% | -32.9% | -19.0% | -11.1% | -6.0% | -24.1% | -16.6% | -15.5% | -5.7% |
ANAB Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
AnaptysBio, Inc. carries a Debt/EBITDA ratio of 0.3x, which is very conservative (91% below the sector average of 3.2x). The company holds a net cash position — cash of $238M exceeds total debt of $14M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns. Interest coverage of just 0.6x is concerning — the company has limited headroom to absorb earnings volatility before struggling with debt service.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.38 | 0.38 | 5.21 | 0.20 | 0.07 | 0.06 | 0.00 | 0.01 | 0.02 | 0.05 | 0.35 |
| Debt / EBITDA | 0.28 | 0.28 | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -6.02 | 3.48 | -0.21 | -0.20 | -1.33 | -0.63 | -0.42 | -0.22 | -0.22 | -0.95 |
| Net Debt / EBITDA | -4.45 | -4.45 | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | -11.43 | — | — | — | — | — | — | — | — | — |
| Interest Coverage | 0.60 | 0.60 | -1.90 | -8.69 | -5.10 | -39.86 | — | -92.65 | -36.44 | -15.94 | -8.30 |
Net cash position: cash ($238M) exceeds total debt ($14M)
ANAB Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
AnaptysBio, Inc.'s current ratio of 9.07x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 10.87x to 9.07x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 9.07 | 9.07 | 9.51 | 10.87 | 17.16 | 34.40 | 20.01 | 12.79 | 19.89 | 17.93 | 10.20 |
| Quick Ratio | 9.07 | 9.07 | 9.51 | 10.87 | 17.16 | 34.40 | 20.01 | 12.79 | 19.89 | 17.93 | 10.20 |
| Cash Ratio | 8.07 | 8.07 | 8.48 | 10.44 | 16.94 | 34.05 | 19.86 | 12.67 | 19.56 | 17.63 | 8.98 |
| Asset Turnover | — | 0.64 | 0.19 | 0.04 | 0.02 | 0.10 | 0.18 | 0.02 | 0.01 | 0.03 | 0.27 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 52.66 | 163.01 | 145.75 | 50.35 | 5.06 | — | — | 12.70 | 58.44 | 116.89 |
ANAB Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
AnaptysBio, Inc. returns 2.7% to shareholders annually primarily through share buybacks.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | 0.8% | 1.9% | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 2.7% | 6.8% | 0.2% | 13.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Total Shareholder Yield | 2.7% | 6.8% | 0.2% | 13.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Shares Outstanding | — | $31M | $28M | $27M | $28M | $27M | $27M | $27M | $25M | $20M | $3M |
Peer Comparison
Compare ANAB with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 ANABYou | $3B | -127.1 | 45.7 | 128.6 | 99.0% | 20.4% | -24.5% | 55.1% | 0.3 |
 RCUS | $3B | -8.8 | — | — | 96.0% | -156.3% | -63.3% | -64.1% | — |
 ARQT | $3B | -210.7 | — | — | 90.2% | -3.3% | -9.3% | -5.2% | — |
 DAWN | $2B | -20.7 | — | — | 89.1% | -80.8% | -22.7% | -30.5% | — |
 FOLD | $5B | -164.8 | 114.9 | 152.4 | 87.3% | 5.4% | -11.6% | 5.3% | 11.5 |
 IMVT | $8B | -13.8 | — | — | — | — | -64.8% | — | — |
 REGN | $65B | 15.0 | 15.6 | 15.9 | 85.4% | 24.9% | 14.9% | 8.9% | 0.7 |
 ABBV | $415B | 99.1 | 17.0 | 23.3 | 70.2% | 32.8% | 6214.7% | 23.9% | 2.4 |
 LLY | $1.1T | 48.7 | 34.9 | 117.7 | 83.8% | 45.6% | 101.2% | 41.8% | 1.4 |
 ALXO | $97M | -0.9 | — | — | — | — | -145.7% | -122.0% | — |
 GSK | $103B | 7.0 | 8.7 | 13.4 | 72.4% | 25.5% | 39.4% | 22.1% | 1.7 |
| Healthcare Median | — | 22.5 | 14.3 | 19.1 | 63.6% | -4.8% | -32.6% | -11.2% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 13 years · Updated daily
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare
ANAB — Frequently Asked Questions
Quick answers to the most common questions about buying ANAB stock.
What is AnaptysBio, Inc.'s P/E ratio?
AnaptysBio, Inc.'s current P/E ratio is -127.1x. This places it at the 50th percentile of its historical range.
What is AnaptysBio, Inc.'s EV/EBITDA?
AnaptysBio, Inc.'s current EV/EBITDA is 45.7x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 15.7x.
What is AnaptysBio, Inc.'s ROE?
AnaptysBio, Inc.'s return on equity (ROE) is -24.5%. The historical average is -36.9%.
Is ANAB stock overvalued?
Based on historical data, AnaptysBio, Inc. is trading at a P/E of -127.1x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are AnaptysBio, Inc.'s profit margins?
AnaptysBio, Inc. has 99.0% gross margin and 20.4% operating margin. Operating margin above 20% indicates strong pricing power and cost efficiency.
How much debt does AnaptysBio, Inc. have?
AnaptysBio, Inc.'s Debt/EBITDA ratio is 0.3x, indicating low leverage. A ratio below 2x is generally considered financially healthy.